References

Anti-mGluR1 encephalitis: Case illustration and systematic review

10.3389/fneur.2023.1142160 · 2023 · External reference

CNS syndromes associated with antibodies against metabotropic receptors

10.1097/wco.0000000000000448 · 2017 · External reference

Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis

10.1212/wnl.0000000000010854 · 2020 · External reference

Autoimmune encephalitis with Anti-mGluR1 antibodies: a comprehensive review

10.1007/s00415-025-13356-x · 2025 · External reference

A clinical approach to diagnosis of autoimmune encephalitis

10.1016/s1474-4422(15)00401-9 · 2016 · External reference

Immune therapy in autoimmune encephalitis: a systematic review

10.1586/14737175.2015.1115720 · 2015 · External reference

Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review

10.1007/s10072-024-07843-8 · 2025 · External reference

Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study

10.1016/s1474-4422(12)70310-1 · 2013 · External reference

Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis

10.1002/ana.24195 · 2014 · External reference

Immunotherapy for autoimmune encephalitis

10.1038/s41420-025-02459-z · 2025 · External reference

Neonatal fc receptor-targeted therapies in neurology

10.1007/s13311-021-01175-7 · 2022 · External reference

Targeting neonatal Fc receptor blockade: reshaping the treatment landscape for IgG-mediated autoimmune diseases

10.3760/cma.j.cn112137-20250308-00560 · 2025 · External reference

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

10.1016/s1474-4422(21)00159-9 · 2021 · External reference

Efgartigimod as rescue treatment in acute phase of neuromyelitis optica spectrum disorder: A Case Report

10.1016/j.heliyon.2024.e30421 · 2024 · External reference

Safety and efficacy of a neonatal fc receptor antagonist in patients with anti-NMDAR encephalitis

10.1111/cns.70534 · 2025 · External reference

A novel case of idiopathic MGluR1 encephalitis in a pediatric patient

10.1177/2329048x221095695 · 2022 · External reference

Cerebellar encephalitis associated with anti-mGluR1 antibodies: a case report and comprehensive literature review

10.3389/fneur.2024.1333658 · 2024 · External reference

Clinical characteristics, treatment, and outcomes in anti-metabotropic glutamate receptor-1 encephalitis: A systematic review

10.1016/j.clineuro.2025.109229 · 2025 · External reference

Efficacy of early rituximab treatment in anti-mGluR1 encephalitis: a case report

10.1186/s12883-025-04345-8 · 2025 · External reference

Immunotherapy in autoimmune encephalitis

10.1097/wco.0000000000001048 · 2022 · External reference

Autoimmune encephalitis: recovery, residual symptoms and predictors of long-term sequelae

10.1136/jnnp-2024-334957 · 2025 · External reference

Case Report: Clinical features and management of anti-mGluR1 encephalitis: case illustration and review of the literature

10.3389/fnint.2025.1580767 · 2025 · External reference

Efgartigimod as a novel FcRn inhibitor for autoimmune disease

10.1007/s10072-024-07460-5 · 2024 · External reference

Efgartigimod for generalized myasthenia gravis and beyond: A narrative review of its pharmacological profile, clinical utility, and expanding applications

10.20944/preprints202511.0402.v1 · 2025 · External reference

Efgartigimod as add-on treatment in refractory guillain-barré Syndrome: A case report

10.1111/ene.70308 · 2025 · External reference

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial

10.1016/s1474-4422(24)00309-0 · 2024 · External reference

Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy

10.3389/fneur.2025.1560483 · 2025 · External reference

Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases

10.1016/j.imlet.2025.106983 · 2025 · External reference

The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors

10.1177/1756286421997381 · 2021 · External reference

The patient perspective in encephalitis research

10.1212/nxi.0000000000200189 · 2024 · External reference

Scale for the assessment and rating of ataxia: development of a new clinical scale

10.1037/t79580-000 · 2006 · External reference